peptides for research
"
सफेद 99% शुद्धता थाइमोसिन अल्फा 1 पेप्टाइड पाउडर थाइमाल्फसिन CAS 69440-99-9 अनुसंधान के लिए
Thymalfasin/Thymosin Alpha 1 Specification: CAS No.: 69440-99-9 Product Name: Thymalfasin/Thymosin Alpha 1 Molecular formula: C129H215N33O55 Molecular weight.: 3108.275 purity: ≥98% Appearance: White or white-like powder or loose lumps Packing Specification: 1g,10g,100g Storage conditions: 2℃~8℃(Short term), -20℃(Long term) Introduction: Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an
99% शुद्धता जीएमपी गुणवत्ता एमओटीएस-सी पाउडर सीएएस 1627580-64-6 अनुसंधान अनुप्रयोगों के लिए
99% Purity GMP Quality MOTS-C Powder CAS 1627580-64-6 Peptide MOTS-C High-purity MOTS-C peptide powder for research applications, manufactured under GMP quality standards. Product Specifications Name MOTS-C CAS Number 1627580-64-6 Appearance White powder Purity 99% Packing Specification 1g, 10g, 100g Storage Conditions 2℃ - 8℃ Molecular Formula C₃₅H₄₈N₁₀O₁₅ Molecular Weight 848.83 g/mol Product Images This product is intended for research purposes only. Manufactured under GMP
नोओपेप्ट क्रिस्टलीय पाउडर 99% शुद्धता GVS-111 आहार पूरक कच्चा माल 157115-85-0
Noopept Powder - 99% Purity GVS-111 High-purity Noopept CAS 157115-85-0 in white crystalline powder form, specifically manufactured for dietary supplement raw materials with 99% purity. Model NO.157115-85-0 EINECS157115-85-0 AppearancePowder QualityIndustrial ColourWhite Molecular Weight318.368 Density1.2±0.1 g/cm3 Melting Point94.0 to 98.0 °c Boiling Point547.3±50.0 °c at 760 Mmhg Name 1Noopept Name 2Omberacetam Name 3CAS 157115-85-0 Noopept Name 4157115-85-0 Name 5Gvs-111
99% शुद्धता CAS 2212020-52-3 Orforglipron पाउडर Glp-1 वजन घटाने Orforglipron
Name:Orforglipron CAS:2212020-52-3 Purity:99% Assay:99% Orforglipron (LY3502970; a GLP-1 receptor agonist 1) is an orally-administerable glucagon-like peptide (GLP-1) receptor agonist, which can be used for research on adult obesity and type 1 diabete Phase II clinical trials have demonstrated that oral Orforglipron at different doses can significantly reduce patients' weight by up to approximately 13% in 26 weeks and up to approximately 15% in 36 weeks, which is comparable
